Sarclisa (isatuximab-irfc), Sarclisa Escena (isatuximab-irfc) Coverage Criteria
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0161 alerts
Get alerted when Policy CC-0161 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-benefit coverage and prior authorization for intravenous Sarclisa (isatuximab-irfc) and subcutaneous Sarclisa Escena in multiple myeloma. Coverage is based on age, diagnosis, prior therapy, transplant eligibility, disease status, and required combination regimens.
Sarclisa Escena (isatuximab-irfc) was added to the clinical criteria and coding.
Coverage criteria were revised to permit Sarclisa IV after one prior line of therapy when used with pomalidomide and dexamethasone.
The diagnosis coding range was expanded to C90.00-C90.32 for multiple myeloma and malignant plasma cell neoplasms.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.